Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin’s Lymphoma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 6, 2025 /PRNewswire/ — Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune... Read more.
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited
Viatris to Receive $400 Million in Cash and $415 Million in Equity Shares of Biocon Limited Transaction Accelerates the Expiration of Biosimilars Non-Compete Restrictions... Read more.
Advances in Technology Help Improve Safety and Access to Blood Cancer Therapies
Emerging tests and treatment strategies guide more tailored approaches and ease the burden on patients ORLANDO, Fla., Dec. 6, 2025 /PRNewswire/ — Four clinical... Read more.
MemeMax, MemeCore’s First Perp DEX, Extends MaxPack Event Ahead of January Launch After 400% Network Surge
SEOUL, South Korea, Dec. 6, 2025 /PRNewswire/ — MemeMax, the first Perp DEX built within the MemeCore ecosystem, has extended its ‘MaxPack Airdrop Campaign’... Read more.
PCs for People Announces Departure of Cofounder and CEO Casey Sorensen After 18 Years of Leadership
ST. PAUL, Minn., Dec. 5, 2025 /PRNewswire/ — PCs FOR PEOPLE announced today that Cofounder and CEO, Casey Sorensen, is departing from his role effective December... Read more.
TODAY SHOW EXPOSES AI MEDICAL SCAMS TARGETING LIPEDEMA PATIENTS
LOS ANGELES, Dec. 5, 2025 /PRNewswire/ — AI-generated deepfake scams are rapidly spreading across social media, using fabricated videos, synthetic voices,... Read more.
Strutt ev¹ the CES 2026 Best of Innovation Winner Announces Super Early Bird Begins
The awards-winning robotics company officially kicks off its pre-order window ahead of its main launch at CES 2026. SINGAPORE, Dec. 5, 2025 /PRNewswire/ —... Read more.
Children’s Education Franchise COMPUCHILD Expands Further Into Santa Clara County, California
Los Gatos, Saratoga Franchisee Adds New Territory of Campbell and Monte Sereno After Strong First-Year Success DUBLIN, Calif., Dec. 5, 2025 /PRNewswire/ — COMPUCHILD,... Read more.
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Dec. 5, 2025 /PRNewswire/ — Nektar Therapeutics (NASDAQ: NKTR) today announced that the Organization and Compensation Committee of Nektar’s... Read more.
AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101 for the Treatment of ALS, Supporting Plans for a Confirmatory Phase 3 Study
Primary safety and tolerability endpoint met AP-101 prolonged survival and delayed need for ventilatory support after 12 months of treatment Functional stabilization... Read more.